CA3162011A1 - Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies - Google Patents

Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies Download PDF

Info

Publication number
CA3162011A1
CA3162011A1 CA3162011A CA3162011A CA3162011A1 CA 3162011 A1 CA3162011 A1 CA 3162011A1 CA 3162011 A CA3162011 A CA 3162011A CA 3162011 A CA3162011 A CA 3162011A CA 3162011 A1 CA3162011 A1 CA 3162011A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
use according
enteric
gdnf
hscr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3162011A
Other languages
English (en)
French (fr)
Inventor
Rodolphe SORET
Nicolas Pilon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus SC
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Publication of CA3162011A1 publication Critical patent/CA3162011A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3162011A 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies Pending CA3162011A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950781P 2019-12-19 2019-12-19
US62/950,781 2019-12-19
PCT/CA2020/051746 WO2021119827A1 (en) 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Publications (1)

Publication Number Publication Date
CA3162011A1 true CA3162011A1 (en) 2021-06-24

Family

ID=76476522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3162011A Pending CA3162011A1 (en) 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Country Status (6)

Country Link
US (1) US20230022970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076499B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665215B2 (cg-RX-API-DMAC7.html)
CA (1) CA3162011A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036928T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021119827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240366723A1 (en) * 2021-06-16 2024-11-07 Transfert Plus, Limited Partnership Combination therapy for the treatment of enteric neuropathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
EP3414322A4 (en) * 2015-12-23 2020-03-04 Memorial Sloan-Kettering Cancer Center CELL THERAPY AND DRUG DISCOVERY BASED ON CELL LINES DERIVED FROM HUMAN ENTERAL NEURAL CREST DERIVED FROM PLURIPOTENT STEM CELLS

Also Published As

Publication number Publication date
EP4076499A4 (en) 2023-11-01
EP4076499B1 (en) 2025-07-16
JP7665215B2 (ja) 2025-04-21
EP4076499A1 (en) 2022-10-26
ES3036928T3 (en) 2025-09-25
JP2023515915A (ja) 2023-04-17
EP4076499C0 (en) 2025-07-16
US20230022970A1 (en) 2023-01-26
WO2021119827A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
Sun et al. Remodeling microenvironment for endogenous repair through precise modulation of chondroitin sulfate proteoglycans following spinal cord injury
EP4076499B1 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
ES2402096T3 (es) Uso de proteínas relacionadas con saposina para prevenir y tratar la obesidad, diabetes y/o síndrome metabólico
US20240366723A1 (en) Combination therapy for the treatment of enteric neuropathies
Souchkova et al. A MOLECULAR-BASED REGENERATIVE MEDICINE APPROACH FOR THE TREATMENT OF HIRSCHSPRUNG DISEAS
WO2007090913A1 (es) Uso de compuestos agonistas de la actividad pi3k en la elaboración de composiciones farmacéuticas, dichas composiciones farmacéuticas y sus aplicaciones en el tratamiento de enfermedades neurodegenerativas
Gao et al. In vivo bioluminescence imaging of hyperglycemia exacerbating stem cells on choroidal neovascularization in mice
Barton Regulation of the Gut-Brain Axis by Guanylyl Cyclase C
Bauch Differentiation, Myelination, and Remyelination of Oligodendroglia and the role of ECM molecules
Krishna Chandran MÜLLER GLIAL CELLS IN EPIRETINAL MEMBRANE FORMATION
Shamloo Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD): Role of Ocular Mucins and Conjunctival Fibrosis
Moghimyfiroozabad C1QL1 & c-KIT molecular complexes: cell surface signaling pathways acting at neuronal synapses and beyond
US20150125432A1 (en) Human Persistent Fetal Vasculature Neural Progenitors for Transplantation in the Inner Retina
Maset Altered migration of forebrain inhibitory interneurons in a mouse model of intellectual disability
Koppinen Enhancing remyelination by overcoming extrinsic and intrinsic inhibitory factors
Talsma Dissecting the Roles of Macrophage Subpopulations Responding to Peripheral Nerve Injury in Conditioning-Lesion Enhanced Regeneration in vivo
King The role of the energy-sensing AMP-activated protein kinase in intestinal epithelial physiology and pathophysiology
di Pisa Oral communications and posters: schedule and abstracts
Shahid Functional compensation among metabotropic receptors involved in cytosolic Ca^< 2+> signaling and satiety control mechanisms
Tao Cell surface proteoglycans control astrocyte migration and retinal angiogenesis by regulating basement membrane assembly
Guyon et al. ÔØ Å ÒÙ× Ö ÔØ
WO2022046771A1 (en) Juvenile protective factors to arrest and reverse aging in the enteric nervous system
MacLean ATP elicits electrophysiological and migratory responses in cells of the spinal cord stem cell niche
Rokkappanavar Optimization of labeling techniques; Determination of best parameter for olfactory mucosal progenitor cell delivery and study of effects of methylene blue and polyethylene glycol in an animal model of spinal cord injury
Ziemba TARGETING AXON GROWTH FROM NEURONS TRANSPLANTEDINTO THE CENTRAL NERVOUS SYSTEM

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240918

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240918

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241118

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250415

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260303